Aura Biosciences (AURA) Cash from Financing Activities (2020 - 2026)
Aura Biosciences' (AURA) quarterly Cash from Financing Activities came in at $300000.0 in Q1 2026, up 212.5% YoY from $96000.0 in Q1 2025, and down 89.16% on a QoQ basis from $2.8 million in Q4 2025.
Aura Biosciences (AURA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Cash from Financing Activities data on file, last reported at $300000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 212.5% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.4 million (up 5279.62% YoY) and the FY2025 annual result came in at $77.2 million, up 4737.3% from the prior year.
- Cash from Financing Activities declined to $300000.0 in Q1 2026, from $2.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $95.2 million in Q4 2022 to a low of $17000.0 in Q1 2022.
- A 5-year average of $16.0 million and a median of $543000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 99.98% — and 2025, when it surged 84151.81%.
- Tracing AURA's Cash from Financing Activities over 5 years: stood at $95.2 million in 2022, then declined by 2.33% to $93.0 million in 2023, then plunged by 99.42% to $543000.0 in 2024, then soared by 409.58% to $2.8 million in 2025, then tumbled by 89.16% to $300000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $300000.0 (Q1 2026), $2.8 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 241.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 241.75 Mn |
| Jun 30, 2026 | 241.75 Mn |
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 2.77 Mn |
| Dec 31, 2025 | 2.77 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | 69.93 Mn |
| Jun 30, 2025 | 69.93 Mn |
| Mar 31, 2025 | 96,000.00 |
| Mar 31, 2025 | 96,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Sep 30, 2024 | 716,000.00 |
| Sep 30, 2024 | 716,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 253,000.00 |
| Mar 31, 2024 | 253,000.00 |